Online inquiry

IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3595MR)

This product GTTS-WQ3595MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets LYPD3 gene. The antibody can be applied in Neoplasms research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_014400.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27076
UniProt ID O95274
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3595MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4489MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ10392MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ3107MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ8920MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ8398MR IVTScrip™ mRNA-Anti-MS4A1, HS006(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HS006
GTTS-WQ3042MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ2618MR IVTScrip™ mRNA-Anti-ICOSLG, AMG 557(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AMG 557
GTTS-WQ6637MR IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DI-17E6
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW